Researchers at the La Jolla Institute for Immunology (LJI) and Scripps Research have successfully used a germline-targeting vaccine to elicit broadly neutralizing antibodies (bnAbs) against HIV in nonhuman primates. Published in Nature, the study demonstrates a method to prime rare immune cells and guide them toward recognizing the virus, a process long considered the primary hurdle in HIV vaccine development.
How does germline targeting differ from traditional vaccines?
Traditional vaccine strategies have struggled to counter HIV due to the virus’s rapid mutation rate and its glycan-shielded envelope. According to the study, germline targeting is a “conceptually radical” design approach. Instead of attempting to force an immediate immune response, it aims to prime rare B cells that possess specific genetic and structural features shared with known bnAbs.
Once these precursor cells are activated, the vaccine uses a sequence of booster shots to “walk” the B cells through affinity maturation. This process guides them from a naive state toward becoming potent, broadly neutralizing antibodies capable of recognizing the virus’s conserved regions.
Broadly neutralizing antibodies are rare proteins that can target conserved, vulnerable sites on the HIV virus, even as the virus changes its shape to evade the immune system.
What were the results of the primate study?
The research team, led by scientists at LJI and Scripps Research, reported that bnAb-class memory B cells were successfully generated in at least 50% of the rhesus macaques tested. Serum bnAb activity was observed in 44% of the animals, according to the published findings.
In the most successful cases, the antibody titers reached levels the authors expect would confer protection against diverse HIV isolates. Co-first author and LJI instructor Patrick Madden, PhD, described the process as a series of vaccinations designed to guide a B cell from its naive state to its final, broadly neutralizing state.
Is this approach being tested in humans?
Human translation is already in progress. The priming immunogen used in the study has been evaluated in the HVTN 144 trial and is currently being tested in the Phase I IAVI G004 trial. Shane Crotty, PhD, LJI professor and CSO, suggested the approach might perform even better in humans, citing potential immunogenetic advantages.
